Spyre Therapeutics, Inc.
SYRE
$16.26
-$0.71-4.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 41.62M | 162.79M | -- | -- | 34.93M |
| Gross Profit | -41.62M | -162.79M | -- | -- | -34.93M |
| SG&A Expenses | 11.94M | 10.77M | 10.65M | 11.51M | 12.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.57M | 61.25M | 55.39M | 44.15M | 47.77M |
| Operating Income | -53.57M | -61.25M | -55.39M | -44.15M | -47.77M |
| Income Before Tax | -44.79M | -56.30M | -69.01M | -38.84M | -43.83M |
| Income Tax Expenses | -15.00K | 1.00K | 18.00K | -- | 32.00K |
| Earnings from Continuing Operations | -44.77M | -56.30M | -69.03M | -38.84M | -43.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.77M | -56.30M | -69.03M | -38.84M | -43.86M |
| EBIT | -53.57M | -61.25M | -55.39M | -44.15M | -47.77M |
| EBITDA | -- | -61.07M | -55.21M | -43.96M | -47.59M |
| EPS Basic | -0.60 | 0.04 | -1.36 | -0.86 | -0.72 |
| Normalized Basic EPS | -0.46 | -0.64 | -0.85 | -0.54 | -0.75 |
| EPS Diluted | -0.60 | 0.04 | -1.36 | -0.86 | -0.72 |
| Normalized Diluted EPS | -0.46 | -0.64 | -0.85 | -0.54 | -0.75 |
| Average Basic Shares Outstanding | 60.27M | 55.26M | 50.89M | 45.32M | 36.51M |
| Average Diluted Shares Outstanding | 60.27M | 55.26M | 50.89M | 45.32M | 36.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |